Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis
(ST) and bleeding, standardized and clinically validated thresholds for accurate risk …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Background Following an acute myocardial infarction (MI), patients with persistently
elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are at …

Background: Post‐treatment platelet reactivity (PR) is associated with ischemic and bleeding
events in patients receiving P2Y12 receptor antagonists. Objectives: We aimed to study the …

The critical role of the coronary microvascular compartment and its invasive functional
assessment has become apparent in light of the significant proportion of patients presenting …

This review is a critical evaluation of publications in the past decade on the usefulness of
platelet function tests (PFTs) in clinical cardiology, in aiding diagnosis, predicting risk, and …

Objective To examine whether prospective bleeding risk estimates for patients undergoing
percutaneous coronary intervention could improve the use of bleeding avoidance strategies …

Background Few studies have examined the effects of on-treatment platelet reactivity on the
risk of major adverse cardiovascular events (MACE). We aimed to determine the optimal …